Graph AI, a fast-growing AI life sciences startup based in California, has announced the successful close of its $3 million seed funding round led by Bessemer Venture Partners. The capital infusion will accelerate product development, expand engineering capabilities, and scale the company’s global reach as it reshapes the $8 billion pharmacovigilance industry with its AI-native platform.
Disrupting an Archaic Industry with AI
Founded in 2024, Graph AI operates in the highly regulated pharmacovigilance sector—where pharmaceutical companies are legally required to monitor, detect, assess, and report adverse drug events (ADEs) throughout a drug’s lifecycle, from clinical trials to post-market surveillance.
Traditionally, these safety processes have relied heavily on large service firms using manual workflows to extract and analyze data from unstructured sources such as call center transcripts, emails, social media, legal filings, and medical literature. These operations are often fragmented, labor-intensive, slow, and error-prone, involving large teams of pharmacology professionals, resulting in delayed signal detection, poor traceability, and higher compliance risks.
Graph AI is challenging this norm with its flagship platform, Graph Safety — a context-aware, AI-native, end-to-end safety solution. The platform automates the entire pharmacovigilance process, including ADE case processing, signal detection, aggregate reporting, and regulatory compliance. It also builds a centralized safety intelligence database, enabling companies to streamline workflows, enhance accuracy, and maintain full audit readiness.
“The life sciences industry has accumulated years of tech debt, operating with outdated systems, siloed data, and inefficient manual processes,” said Raghav Parvataraju, co-founder and CEO of Graph AI. “We saw an opportunity to reimagine pharmacovigilance with a SaaS-based, AI-powered approach that’s faster, smarter, and truly scalable.”
Strong Early Traction and Global Ambitions
In just its first year, Graph AI has made significant strides. The company already supports a pipeline of over 7,000 marketed drugs across pharmaceutical, biotech, cosmetic, and clinical research organizations (CROs). Enterprise customers report up to 70% efficiency gains, 90% faster regulatory reporting, and substantial cost savings while maintaining full compliance and traceability.
The company’s core customers are concentrated in the U.S., followed by Europe, where stringent pharmacovigilance regulations drive innovation, and the Asia-Pacific region, including India, Japan, and China.
“Our platform brings together AI, automation, and regulatory intelligence into one seamless system. This not only improves efficiency but also boosts confidence among regulators and stakeholders,” said Mohan Konyala, Chief Product Officer.
AI at the Core: From Data to Decisions
Graph AI’s innovation lies not just in automation, but in the depth of its AI technology. The company has developed an in-house generative AI studio that powers everything from data ingestion and scripting to multilingual translation, regulatory report generation, sentiment analysis, ad creation, and predictive analytics. This drastically reduces manual workloads, speeds up decision-making, and enhances the consistency of data extraction from both structured and unstructured sources.
“Graph’s platform represents the shift from labor arbitrage to intelligence arbitrage—where value is delivered not by headcount, but by speed, accuracy, and adaptability,” said Nithin Kaimal, Partner and COO at Bessemer Venture Partners India. “We believe Graph AI is at the forefront of transforming traditional pharma services into intelligent digital systems.”
Leadership with Deep Tech and Pharma DNA
Graph AI was co-founded by a seasoned leadership team:
- Raghav Parvataraju, CEO
- Vijay Ponukumati, CTO
- Mohan Konyala, CPO
- Ashutosh Bordekar, CFO
The founders bring a rich blend of experience from leading firms like Google, Cisco, ServiceNow, Infosys, and LTI Mindtree, spanning enterprise tech, outsourcing, and life sciences. The company currently employs 18 people across offices in Silicon Valley (headquarters), Hyderabad, India (engineering), and Bogotá, Colombia (support and data operations).
“We’ve intentionally built a cross-functional team with both domain experts and AI engineers to ensure our platform isn’t just technologically advanced, but also regulatory-grade,” said Vijay Ponukumati, Chief Technology Officer.
What’s Next for Graph AI
With the latest funding, Graph AI plans to:
- Accelerate product innovation and expand platform features
- Grow its engineering and AI teams, especially in India and Colombia
- Deepen penetration in North America, Europe, and Asia-Pacific
- Continue collaborating with regulatory bodies to ensure evolving compliance
The company’s long-term vision is to become the de facto safety intelligence platform for life sciences, enabling pharmaceutical companies to not only meet compliance but to proactively predict and prevent safety risks.
“Our mission is to make patient safety smarter, faster, and more connected,” the founders emphasized in a joint statement. “We’re enabling a new era of pharmacovigilance where intelligence, not manpower, leads the way.”
About Graph AI
Founded in 2024, Graph AI is an AI life sciences company focused on automating pharmacovigilance and patient safety operations. Its flagship platform, Graph Safety, leverages context-aware AI and automation to streamline adverse event reporting, regulatory compliance, and safety intelligence across the drug development lifecycle.
About Bessemer Venture Partners
Bessemer is one of the world’s most respected venture capital firms with a strong focus on technology and healthcare. The firm has backed iconic companies such as LinkedIn, Twilio, Shopify, and Pinterest, and continues to invest in category-defining AI startups globally.